Silexion Therapeutics Ltd. (SLXN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol SLXN
- Company Silexion Therapeutics Ltd.
- Price $0.46
- Changes Percentage -12.78
- Change -0.0677
- Day Low $0.44
- Day High $0.52
- Year High $22.36
- Year Low $0.23
- Market Cap $266,570
- Price Avg 50 EMA (D) $0.98
- Price Avg 200 EMA (D) $2.83
- Exchange NASDAQ
- Volume 5,492,671
- Average Volume 5,451,312
- Open $0.44
- Previous Close $0.53
- EPS -8.96
- PE -0.05
- Earnings Announcement 2026-08-11 04:00:00
- Shares Outstanding $560,964
Company brief: SILEXION THERAPEUTICS LTD. (SLXN )
- Healthcare
- Biotechnology
- Mr. Ilan Hadar M.B.A.
- https://silexion.com
- IL
- N/A
- 04-07-2021
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
SLXN Corporation News
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
globenewswire.com -- Israeli Ministry of Health approved the initiation of Silexion's Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer...